NAS8
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
01/13/2026
Back to search
Official data from USPTO
FORMA THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
FORMA THERAPEUTICS
ST13
US500000087944961Class
1, 5, 42, 44
Filing
87944961
Registration
5689302
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
43
Latest update
02/03/2026
Trademark type
Word
Nice classes
1, 5, 42, 44
Filing date
06/01/2018
Registration date
03/05/2019
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/13/2026
Last transaction
02/03/2026
Responsible office
United States Patent and Trademark Office
Status code
704
Official register
Principal Register
First use anywhere
12/01/2008
First use in commerce
12/01/2008
Drawing code
4
Owner type
03
Owner location
Watertown, MA
Examiner
STOIDES, KATHERINE
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Forma Therapeutics, Inc.
Representatives
Edward T. White Williams Mullen Center
Technical classification
Nice Classes
Class 1Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
chemical compounds for use in bio-pharmaceutical research
Class 5
Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of inflammation; pharmaceutical preparations for the treatment of immune-mediated conditions; pharmaceutical preparations for the treatment of neuro-degenerative diseases
Class 42
research and development of pharmaceuticals for others ; research and development of pharmaceuticals for the treatment of cancer; research and development of pharmaceuticals for the treatment of inflammations; research and development of pharmaceuticals for the treatment of immune-mediated conditions; research and development of pharmaceuticals for the treatment of neuro-degenerative diseases; scientific and medical research in the fields of oncologyimmunology and immune-oncologyinflammationimmune-mediated diseasesprotein homeostasisepigenetics and protein metabolism
Class 44
Providing a web site featuring information relating to the biology of potential medical treatment such as protein homeostasisepigeneticsprotein metabolism and/or immunology
Publications
History of USPTO decisions and trademark events.
43 publications found
8.PR
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED
01/13/2026
PRAN
POST REGISTRATION ACTION MAILED NO RESPONSE REQUIRED
01/13/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
01/13/2026
ES8R
TEAS SECTION 8 RECEIVED
09/04/2025
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
03/05/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
09/10/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
09/10/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
09/10/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
09/10/2021
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
09/10/2021
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
04/14/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/14/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/14/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/14/2021
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
04/14/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
03/05/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/18/2018
PUBO
PUBLISHED FOR OPPOSITION
12/18/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/28/2018
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
11/09/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/08/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/08/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/08/2018
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
11/05/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/15/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/15/2018
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
10/09/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/03/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/03/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/24/2018
XAEC
EXAMINER'S AMENDMENT ENTERED
09/21/2018
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
09/21/2018
GNEA
EXAMINERS AMENDMENT E-MAILED
09/21/2018
CNEA
EXAMINERS AMENDMENT -WRITTEN
09/21/2018
CEPE
COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION ENTERED
09/21/2018
ALIE
ASSIGNED TO LIE
09/21/2018
GEAN
NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
09/21/2018
GEAP
EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
09/21/2018
CPEA
EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED
09/21/2018
DOCK
ASSIGNED TO EXAMINER
09/20/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/07/2018
NWAP
NEW APPLICATION ENTERED
06/05/2018
Continuous trademark protection
Get notified about every new filing that threatens FORMA THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.